Zydus Lifesciences Ltd.
NSE: ZYDUSLIFEZydus Lifesciences Ltd.: A 30-second snapshot
Zydus Lifesciences (Rs 939.25) trades marginally below its 200-DMA of Rs 941.75 with RSI at 55.77 and a 1-year price gain of 8.12%. The stock carries the lowest trailing PE (20.2) among 6 pharma peers in the dataset and ranks 2nd of 6 on quality score (51). A 30.3% 5-year revenue CAGR has translated into only 1.9% earnings growth over the same period, a divergence that frames the current valuation discount.
P/E
20.2
Forward P/E
23.7
ROE
—
Debt / Equity
34.30
Profit Margin
+18.9%
Div. Yield
+1.2%
5Y ROE > 15%
3/5
5Y FCF > 0
4/5
Quality
62/100
News
8 headlines · 5 positive · 0 negative
Zydus Life Share Buyback: All you need to know as a shareholder - CNBC TV18
CNBC TV18
Zydus Subsidiary Completes Euro 700,000 Acquisition of French Medical Distributor - scanx.trade
scanx.trade
Zydus Receives DCGI Approval for Phase III Trials of Anti-Malarial Zintrodiazine - scanx.trade
scanx.trade
Zydus Lifesciences Receives USFDA Approval for Oncology Injectable Facility - scanx.trade
scanx.trade
Here's why today and May 19 are important sessions for Zydus Life shareholders - CNBC TV18
CNBC TV18
Recent context
- ·A share buyback is underway with key shareholder dates on 15 May and 19 May 2026 per CNBC TV18 reporting; a subsidiary also completed a Euro 700,000 acquisition of a French medical distributor in early May.
- ·USFDA approved the oncology injectable facility (April 2026) and DCGI granted Phase III trial clearance for Zintrodiazine anti-malarial (April 2026), representing concurrent regulatory milestones across different product categories.
- ·News sentiment across 8 articles is 5 positive, 3 neutral, 0 negative; the positive skew reflects regulatory approvals and the buyback announcement rather than earnings or margin-related developments.
Strengths
- +Lowest trailing PE in the peer group at 20.2, compared to sector peers ranging from 25.9 (DRREDDY) to 72.0 (MAXHEALTH) -- a discount of at least 28% to the next-closest peer on this metric.
- +FCF positive in 4 of available tracked years with debt trend reported as falling; D/E at approximately 0.34 on a standard basis suggests a manageable leverage trajectory.
- +Active regulatory pipeline: USFDA approval received for an oncology injectable facility and DCGI Phase III clearance granted for anti-malarial candidate Zintrodiazine in April-May 2026.
- +Consistency score of 71 and a 29-analyst coverage base reflecting sustained institutional research interest; ROE above 15% in 3 of the tracked years.
Weaknesses
- −5-year earnings CAGR of 1.9% against revenue CAGR of 30.3% points to significant operating leverage failure or cost base expansion over the same horizon.
- −Price has been tracking near and below the 200-DMA; the stock sits 11.31% below its 52-week high with the 200-DMA (Rs 941.75) acting as immediate resistance.
- −ROE is unavailable in the dataset, preventing direct comparison on return metrics against pharma peers; quality score of 51 is mid-pack in the sector sample.
- −Share buyback (May 2026) with key shareholder dates on 15 May and 19 May introduces a near-term corporate event whose outcome for non-participating shareholders remains pending.
Open questions
- ?Does the persistent gap between 30.3% revenue growth and 1.9% earnings growth over 5 years reflect a structural cost issue in the business model, or a transitional phase tied to capacity investment?
- ?How does the ongoing buyback affect the company capital allocation priorities, and what does it signal about management's view of intrinsic value versus other uses of cash?
- ?With the 200-DMA acting as immediate resistance and the forward PE (23.7) higher than the trailing PE (20.2), what earnings recovery assumptions are embedded in the current valuation?
- ?Across the USFDA-approved oncology injectable facility and the DCGI Phase III anti-malarial trial, which pipeline asset represents the larger addressable market and over what horizon could it contribute meaningfully to earnings?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ZYDUSLIFE | Zydus Lifesciences Ltd.You're viewing | 20.2 | — | 51 |
| Industry avg | across 5 peers | 46.7 | +11.8% | 38 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.0 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.0 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.9 | — | 25 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 25.9 | +11.8% | 17 |
Technical state
Current price
₹939.25
SMA 50
₹910.45
SMA 200
₹941.75
RSI (14)
55.8 (neutral)
From 52w high
-11.3%
1Y return
+8.1%
3M return
+1.7%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- medium5-year earnings growth of 1.9% contrasts with 5-year revenue growth of 30.3%, suggesting margin compression or cost escalation; current profit margin is 18.93%.
- mediumPrice of Rs 939.25 is marginally below the 200-DMA of Rs 941.75 and has been tracking near that level; 1-year price change of 8.12% is modest relative to the 11.31% drawdown from 52-week high.
- lowD/E ratio of 34.305 (reported on percentage basis, approximately 0.34 standard) and ROE unavailable in the dataset, limiting quality benchmarking against pharma peers.
- lowNews sample of 8 articles is sparse; the small count reduces sentiment signal reliability despite the positive overallLabel.
Cross-section contradictions
- Revenue grew 30.3% over 5 years while earnings grew only 1.9% -- either operating leverage did not materialise or cost structures expanded materially; yet the current PE of 20.2 sits at the lowest among the 6 peers ranked, suggesting the market has already discounted the weak earnings trajectory.
- News flow contains both a USFDA oncology injectable facility approval and a DCGI Phase III trial clearance alongside a share buyback announcement within the same fortnight -- concurrent corporate activity and regulatory approvals are driving the positive news skew rather than core operating momentum.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 14 May 2026 · rotates through NIFTY 500 every ~5 days